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Development of a UK national 
prescribing sKills assessment
S. Maxwell*
Clinical Pharmacology Unit, University of Edinburgh, Edinburgh, 
United Kingdom
Summary: Prescribing of medicines is the key clinical activity in the 
working life of most doctors. In recent years, a broad consensus 
regarding the necessary competencies has been achieved. Each of 
these is a complex mix of knowledge, judgment, and skills. Surveys 
of those on the threshold of their medical careers have revealed wide-
spread lack of confidence in writing prescriptions. A valid and reli-
able assessment of prescribing competence, separate from an overall 
assessment of medical knowledge and skill, would have many benefits 
for clinical governance and patient safety, and would provide a meas-
ure of the success of training programs in therapeutics. Delivering 
such an assessment presents many challenges, not least of which 
are the difficulty in identifying a surrogate marker for competent 
prescribing in clinical practice and the challenge of ensuring that com-
petence assessed in a controlled environment predicts performance 
in clinical practice. This talk will describe the approach being used 
in the United Kingdom to develop an online “OSCE” assessment 
of prescribing and sets out the requirements for its development, 
scope, composition, and delivery. It will describe the current status in 
the development and implementation of the UK national Prescribing 
Skills Assessment for final-year medical students.
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Summary: During the past few years, several new classes of anti-
diabetic drugs have appeared on the market, such as glucagon-like-
peptide analogs, dipeptidyl peptidase-4 inhibitors, renal glucose 
reuptake inhibitors, and insulin analogues with different kinetic 
properties. Although these drugs have mostly very attractive modes 
of action, their use in clinical practice can be limit by nonsuperiority 
with regard to existing treatments, and increased costs, as well as the 
lack of knowledge on hard end points and long-term safety. This is of 
particular concern with regard to cardiovascular protection or risks, 
as has become evident from the past experience, for example, with 
rosiglitazone. A possible solution to this problem is to individualize 
antidiabetic therapy by taking into account the age, obesity, renal 
function, and therapeutic compliance, as well as other factors of 
the patient, with the aim of choosing drugs that offer individualized 
additional benefits for selected patients.
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assessment of DrUg-inDUceD liver injUry 
from clinical trial Data
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Summary: Proper analysis of liver safety data is multivariate by 
nature and has to take into account time dependency of observa-
tions. Current standard tools for liver safety assessment are summary 
tables, individual data listings, narratives, and static graphs. An effi-
cient complementary approach is use of interactive graphics, ideally 
in a team-based setting. A systematic workflow including predefined 
graph templates helps to ensure completeness of evaluations, sup-
ports hypothesis generation and testing, and facilitates identification 
of the most suitable graphics for publishing and regulatory reporting. 
The use of interactive graphics instead of focusing on static graphs 
enables a project team to jointly assess biomarker data, helps to 
thoroughly query the data from different perspectives, and fosters 
team ownership of both analysis and conclusions. This talk presents 
a systematic workflow for liver safety assessment using a series of 
interactive graph templates.
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Summary: Today, drugs play an important role in human disease 
prevention and treatment, as well as protection of health. In China, 
along with the development of medicines and the health care system, 
rational drug use and drug safety are becoming increasingly impor-
tant concerns. In the early 1980s, the Chinese government started to 
carry out pilot projects to monitor ADR. In March 1998, we formally 
joined the WHO International Drug Monitoring Program. After 
nearly 20 years of practice, China ADR monitoring was strength-
ened in terms of legal framework, monitoring systems, information 
technology application, administrative control, capital investment, 
and other aspects. Although China’s ADR monitoring has devel-
oped rapidly, we still face many challenges. The revised edition of 
“Management Measures of Adverse Drug Reactions Reporting and 
Monitoring” had been promulgated in July 2011, with the intent to 
further standardize the requirements and procedures of ADR report-
ing. We also intend to intensify the verification, investigation, and 
evaluation of case reports. We also continue to strengthen exchange 
and communication with WHO and other countries on drug safety 
information. We hope to learn best practices and encourage innova-
tion in China’s ADR monitoring system to ensure rational and safe 
use of drugs.
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Summary: Sjögren’s syndrome is a systemic autoimmune disease 
that results in tear film instability, hyperosmolarity, chronic irrita-
tion, and inflammation of the ocular surface. Treatment can be 
either conservative or invasive based on the severity of the disease. 
The basic aim of the treatment is to improve the quality of life and 
reduce subjective complaints and objective ocular surface irrita-
tion. The first line of treatment is tear substitution with artificial 
tear drops, gels, and ointments. In moderate cases, preservative-
free tear supplementation, topical anti-inflammatory therapy, and 
retinol treatment is recommended. Temporary or permanent punc-
tal plug occlusion, therapeutic contact lenses, or using a moisture 
chamber can also be an option. In severe cases, the application 
of topical autologous serum, systemic anti-inflammatory therapy, 
androgen substitution, secretagogues, and surgical intervention can 
be effective. As a future perspective, causal therapy of the disease 
will play a greater role, such as cyclosporine therapy, secretion 
stimulation, growth factor containing artificial tears, and immu-
nomodulants.
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